Format

Send to

Choose Destination
J Clin Oncol. 2019 Oct 25:JCO1901740. doi: 10.1200/JCO.19.01740. [Epub ahead of print]

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Author information

1
Emory University, Atlanta, GA.
2
Dana Farber Cancer Institute, Boston, MA.
3
Mayo Clinic, Scottsdale, AZ.
4
ThedaCare Cancer Center, Appleton, WI.
5
Mayo Clinic, Rochester, MN.
6
MD Anderson Cancer Center, Houston, TX.
7
University of Kansas Cancer Center, Westwood, KS.
8
MetroHealth Medical Center, Cleveland, OH.
9
Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO.
10
Park Nicollet Clinic, Saint Louis Park, MN.
11
University of Louisville, Louisville, KY.
12
Scripps Clinic Torrey Pines, La Jolla, CA.
13
Wake Forest University Health Sciences, Winston-Salem, NC.

Abstract

PURPOSE:

Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma.

METHODS:

We conducted a randomized trial that assessed the efficacy of single-agent lenalidomide compared with observation in patients with intermediate- or high-risk smoldering multiple myeloma. Lenalidomide was administered orally at a dose of 25 mg on days 1 to 21 of a 28-day cycle. The primary end point was progression-free survival, with disease progression requiring the development of end-organ damage attributable to multiple myeloma and biochemical progression.

RESULTS:

One hundred eighty-two patients were randomly assigned-92 patients to the lenalidomide arm and 90 to the observation arm. Median follow-up is 35 months. Response to therapy was observed in 50% (95% CI, 39% to 61%) of patients in the lenalidomide arm, with no responses in the observation arm. Progression-free survival was significantly longer with lenalidomide compared with observation (hazard ratio, 0.28; 95% CI, 0.12 to 0.62; P = .002). One-, 2-, and 3-year progression-free survival was 98%, 93%, and 91% for the lenalidomide arm versus 89%, 76%, and 66% for the observation arm, respectively. Only six deaths have been reported, two in the lenalidomide arm versus four in the observation arm (hazard ratio for death, 0.46; 95% CI, 0.08 to 2.53). Grade 3 or 4 nonhematologic adverse events occurred in 25 patients (28%) on lenalidomide.

CONCLUSION:

Early intervention with lenalidomide in smoldering multiple myeloma significantly delays progression to symptomatic multiple myeloma and the development of end-organ damage.

PMID:
31652094
DOI:
10.1200/JCO.19.01740

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center